Neurocrine biosciences announces results from the real-world re-kinect™ study published in the journal of patient-reported outcomes demonstrating the effects of possible tardive dyskinesia (td) on patient health and social functioning

San diego , march 9, 2023 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) announced today that new data from re-kinect™, the largest real-world, observational, multicenter study of antipsychotic-treated patients with possible tardive dyskinesia (td), was published in the journal of patient-reported outcomes. 1 the analysis assessed the effects of possible td, defined as clinician-confirmed presence of abnormal involuntary movements, on patient health and social functioning.
NBIX Ratings Summary
NBIX Quant Ranking